Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List    Related articles in Annals    CME course  Services    Send comment/rapid response letter    Published comments/rapid response letters    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Bartlett, J. G.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease

John G. Bartlett, MD

21 November 2006 | Volume 145 Issue 10 | Pages 758-764

Antibiotic-associated diarrhea and colitis were well established soon after antibiotics became available. Early work implicated Staphylococcus aureus, but in 1978 Clostridium difficile became the established pathogen in the vast majority of cases. In the first 5 years (1978 through 1983), the most common cause was clindamycin, the standard diagnostic test was the cytotoxin assay, and standard management was to withdraw the implicated antibiotic and treat with oral vancomycin. Most patients responded well, but 25% relapsed when vancomycin was withdrawn. During the next 20 years (1983 through 2003), the most commonly implicated antibiotics were the cephalosporins, which reflected the rates of use; the enzyme immunoassay replaced the cytotoxin assay because of speed of results and technical ease of performance; and metronidazole replaced vancomycin as standard treatment, and principles of containment hospitals became infection control and antibiotic control. During the recent past (2003 to 2006), C. difficile has been more frequent, more severe, more refractory to standard therapy, and more likely to relapse. This pattern is widly distributed in the United States, Canada, and Europe and is now attributed to a new strain of C. difficile designated BI, NAP1, or ribotype 027 (which are synonymous terms). This strain appears more virulent, possibly because of production of large amounts of toxins, and fluoroquinolones are now major inducing agents along with cephalosporins, which presumably reflects newly acquired in vitro resistance and escalating rates of use. The recent experience does not change principles of management of the individual patient, but it does serve to emphasize the need for better diagnostics, early recognition, improved methods to manage severe disease and relapsing disease, and greater attention to infection control and antibiotic restraint.

Author and Article Information

From John Hopkins University School of Medicine, Baltimore, Maryland.

Potential Financial Conflicts of Interest: Consultancies: Dr. Bartlett is on the HIV advisory boards of Abbott, Bristol-Myers Squibb, and GlaxoSmithKline Pharmaceuticals.

Requests for Single Reprints: John G. Bartlett, MD, Department of Medicine, Johns Hopkins University School of Medicine, 1830 Monument Street, 437, Baltimore, MD 21205; e-mail, jb{at}jhmi.edu.

Related articles in Annals:

Letters
Hand Hygiene and Clostridium difficile
Ted W. Gay

Annals 2007 147: 69-70. [Full Text]  

This article has been cited by other articles:

				N. Vernaz, H. Sax, D. Pittet, P. Bonnabry, J. Schrenzel, and S. Harbarth Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile J. Antimicrob. Chemother., September 1, 2008; 62(3): 601 - 607. [Abstract] [Full Text] [PDF]

				T. Pelaez, E. Cercenado, L. Alcala, M. Marin, A. Martin-Lopez, J. Martinez-Alarcon, P. Catalan, M. Sanchez-Somolinos, and E. Bouza Metronidazole Resistance in Clostridium difficile Is Heterogeneous J. Clin. Microbiol., September 1, 2008; 46(9): 3028 - 3032. [Abstract] [Full Text] [PDF]

				K. Sanchez-Hurtado, M. Corretge, E. Mutlu, R. McIlhagger, J. M. Starr, and I. R. Poxton Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls J. Med. Microbiol., June 1, 2008; 57(6): 717 - 724. [Abstract] [Full Text] [PDF]

				C. Deneve, C. Delomenie, M.-C. Barc, A. Collignon, and C. Janoir Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression J. Med. Microbiol., June 1, 2008; 57(6): 732 - 738. [Abstract] [Full Text] [PDF]

				J. E. Emerson, R. A. Stabler, B. W. Wren, and N. F. Fairweather Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress J. Med. Microbiol., June 1, 2008; 57(6): 757 - 764. [Abstract] [Full Text] [PDF]

				T Monaghan, T Boswell, and Y R Mahida Recent advances in Clostridium difficile-associated disease Gut, June 1, 2008; 57(6): 850 - 860. [Abstract] [Full Text] [PDF]

				A. Samie, C. L. Obi, J. Franasiak, L. Archbald-Pannone, P. O. Bessong, C. Alcantara-Warren, and R. L. Guerrant PCR Detection of Clostridium difficile Triose Phosphate Isomerase (tpi), Toxin A (tcdA), Toxin B (tcdB), Binary Toxin (cdtA, cdtB), and tcdC Genes in Vhembe District, South Africa Am J Trop Med Hyg, April 1, 2008; 78(4): 577 - 585. [Abstract] [Full Text] [PDF]

				P. H. Gilligan Is a Two-Step Glutamate Dehyrogenase Antigen-Cytotoxicity Neutralization Assay Algorithm Superior to the Premier Toxin A and B Enzyme Immunoassay for Laboratory Detection of Clostridium difficile? J. Clin. Microbiol., April 1, 2008; 46(4): 1523 - 1525. [Abstract] [Full Text] [PDF]

				E. Kokkotou, A. C. Moss, A. Michos, D. Espinoza, J. W. Cloud, N. Mustafa, M. O'Brien, C. Pothoulakis, and C. P. Kelly Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1121 - 1126. [Abstract] [Full Text] [PDF]

				M. E. Reller, C. A. Lema, T. M. Perl, M. Cai, T. L. Ross, K. A. Speck, and K. C. Carroll Yield of Stool Culture with Isolate Toxin Testing versus a Two-Step Algorithm Including Stool Toxin Testing for Detection of Toxigenic Clostridium difficile J. Clin. Microbiol., November 1, 2007; 45(11): 3601 - 3605. [Abstract] [Full Text] [PDF]

				D. W. Hecht, M. A. Galang, S. P. Sambol, J. R. Osmolski, S. Johnson, and D. N. Gerding In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2716 - 2719. [Abstract] [Full Text] [PDF]

				D. Livermore The zeitgeist of resistance J. Antimicrob. Chemother., August 1, 2007; 60(suppl_1): i59 - i61. [Abstract] [Full Text] [PDF]

				C. Kenneally, J. M. Rosini, L. P. Skrupky, J. A. Doherty, J. M. Hollands, E. Martinez, W. McKenzie, T. Murphy, J. R. Smith, S. T. Micek, et al. Analysis of 30-Day Mortality for Clostridium difficile-Associated Disease in the ICU Setting Chest, August 1, 2007; 132(2): 418 - 424. [Abstract] [Full Text] [PDF]

				T. W. Gay Hand Hygiene and Clostridium difficile Ann Intern Med, July 3, 2007; 147(1): 69 - 70. [Full Text] [PDF]

				T. K. Lu and J. J. Collins Dispersing biofilms with engineered enzymatic bacteriophage PNAS, July 3, 2007; 104(27): 11197 - 11202. [Abstract] [Full Text] [PDF]

				M. Segarra-Newnham Probiotics for Clostridium difficile-Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii Ann. Pharmacother., July 1, 2007; 41(7): 1212 - 1221. [Abstract] [Full Text] [PDF]

				C. Ghose, A. Kalsy, A. Sheikh, J. Rollenhagen, M. John, J. Young, S. M. Rollins, F. Qadri, S. B. Calderwood, C. P. Kelly, et al. Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice Infect. Immun., June 1, 2007; 75(6): 2826 - 2832. [Abstract] [Full Text] [PDF]

				An Epidemic of C. difficile Disease Journal Watch Emergency Medicine, January 19, 2007; 2007(119): 3 - 3. [Full Text]

Rapid Responses: